233 - PSF3 is a novel prognostic biomarker in lung adenocarcinoma

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Daisuke Hokka
Authors D. Hokka1, Y. Maniwa2, S. Tane2, S. Tauchi2, W. Nishio2, M. Yoshimura2
  • 1Division Of Thoracic Surgery, Department Of Surgery, Kobe University Graduate School of Medicine, 650-0017 - KOBE/JP
  • 2Divisions Of Thoracic Surgery, Department Of Surgery, Kobe University Graduate School of Medicine, 650-0017 - KOBE/JP

Abstract

Background

PSF3 is a member of the highly evolutionarily conserved tetrameric complex termed GINS, composed of SLD5, PSF1, PSF2, and PSF3. Previous studies suggested that some GINS complex members are upregulated in cancer, but PSF3 expression in lung adenocarcinoma has not been investigated. The objective of the current study was to elucidate the role of PSF3 in lung adenocarcinoma by investigating clinical samples.

Methods

We investigated the expression of PSF3 in cancer epithelial cells immunohistochemically in 125 consecutive resected cases of lung adenocarcinoma.

Results

Increased PSF3 expression was observed in 27 (21.6%) of the 125 cases. PSF3 expression was found to be correlated significantly with some clinicopathological factors. A univariate analysis and log–rank test indicated a significant association between PSF3 expression and lower overall survival rate (P = 0.0001 and P < 0.0001, respectively). A multivariate analysis also indicated a statistically significant association between increased PSF3 expression and lower overall survival rate (hazard ratio, 5.2; P = 0.0027). In a subgroup analysis of only stage I patients, increased PSF3 expression was also significantly associated with a lower overall survival rate (P = 0.0008, log–rank test). Moreover, the Ki67 index level was higher in the PSF3- positive group than in the negative group (P < 0.0001, Mann–Whitney U-test).

Conclusion

The current results indicated that PSF3 is a novel prognostic biomarker in lung adenocarcinoma.

Disclosure

All authors have declared no conflicts of interest.